PLUS1
0.815
-0.0104 (-1.26%)
-0.0104 (-1.26%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AzurRx BioPharma Inc | AZRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.0104 | -1.26% | 0.815 | 00:00:05 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 0.815 | 0.710001 | 0.826 | 0.72 | 0.8254 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.72 | 1.38 | 0.66 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 788 | 578,364 | $ 0.7474913 | $ 432,322 | 578,668 | 0.370868 - 1.9383 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:01 | 66,533 | $ 0.815 | USD |
AzurRx BioPharma Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 23.23M | 28.50M | 27.52M | $ - | $ - | -0.70 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 4.80% |
AzurRx BioPharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/17/2020 | 17:25 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 9/17/2020 | 17:22 | Edgar (US Regulatory) | Withdrawal of Registration Statement (rw) |
| 9/14/2020 | 09:29 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/21/2020 | 16:36 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/14/2020 | 16:31 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 8/12/2020 | 16:37 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/11/2020 | 17:23 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AZRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7408 | 0.86 | 0.7045 | 0.7691226 | 123,414 | 0.0742 | 10.02% |
| 1 Month | 0.89 | 0.8923 | 0.7045 | 0.7831622 | 198,482 | -0.075 | -8.43% |
| 3 Months | 0.9257 | 1.40 | 0.7045 | 0.9870648 | 352,846 | -0.1107 | -11.96% |
| 6 Months | 0.58 | 1.40 | 0.50 | 0.8651448 | 316,590 | 0.235 | 40.52% |
| 1 Year | 1.05 | 1.9383 | 0.370868 | 0.9574962 | 372,374 | -0.235 | -22.38% |
| 3 Years | 4.32 | 5.25 | 0.370868 | 1.34 | 186,847 | -3.51 | -81.13% |
| 5 Years | 5.06 | 5.60 | 0.370868 | 1.45 | 148,775 | -4.25 | -83.89% |
AzurRx BioPharma Description
| AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). |
